• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Quince Therapeutics, Inc. - Common Stock (NQ: QNCX )

    0.6400 +0.0300 (+4.92%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 203,463
    Open 0.6100
    Bid (Size) 0.6300 (20)
    Ask (Size) 0.6545 (2)
    Prev. Close 0.6100
    Today's Range 0.5609 - 0.6400
    52wk Range 0.5116 - 1.430
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
    Via Benzinga

    Performance

    YTD
    -38.46%
    -38.46%
    1 Month
    -15.23%
    -15.23%
    3 Month
    -28.09%
    -28.09%
    6 Month
    -52.24%
    -52.24%
    1 Year
    -48.39%
    -48.39%

    More News

    Read More
    Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
    From Quince Therapeutics, Inc.
    Via Business Wire
    QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
    Via InvestorPlace
    Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
    From Quince Therapeutics, Inc.
    Via Business Wire
    QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
    Via InvestorPlace
    Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
    From Quince Therapeutics, Inc.
    Via Business Wire
    QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
    Via InvestorPlace
    Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics Launches Scientific Advisory Board
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics to Participate at Investor Events in January 2024
    From Quince Therapeutics, Inc.
    Via Business Wire
    SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Quince Therapeutics Completes Acquisition of EryDel S.p.A.
    From Quince Therapeutics, Inc.
    Via Business Wire
    Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics Appoints Dr. Charles S. Ryan as President
    From Quince Therapeutics, Inc.
    Via Business Wire
    Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
    From Quince Therapeutics, Inc.
    Via Business Wire
    Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.